Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma. (October 2021)

• Record Type: Journal Article
• Authors: Oberic, Lucie; Delzor, Faustine; Protin, Caroline; Perriat, Sophie; Laurent, Camille; Grand, Anaïs; Canonge, Jean Marie; Borel, Cécile; Gauthier, Martin; Ysebaert, Loïc; Puisset, Florent
• Is Part Of: Journal of oncology pharmacy practice. Volume 27:Number 7(2021)
• Page Start: 1730
• Page End: 1735
• Publication Date: 2021-10
• Subjects: Brentuximab vedotin -- T-cell lymphoma -- combination chemotherapy -- refractory/relapse PTCL; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220968615
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Brentuximab vedotin (Bv) has been approved for the treatment of Refractory/Relapsed (R/R) Anaplastic Large Cell Lymphomas (ALCL) and cutaneous T-Cell Lymphomas, but is also effective in other CD30+ malignancies. We report here the outcomes of patients with various R/R Peripheral T Cell Lymphoma (PTCL) treated with Bv in real life practice. Method: This was a retrospective, single-center study based on medical records of patients with R/R PTCL treated either with Bv alone or in combination with chemotherapy. Results: Among 27 patients treated with Bv, neutropenia was the main serious adverse event observed in particular when Bv was used as combination treatment. The complete Response Rates (CRR) was 40.7%; it was significantly improved when Bv was used as combination treatment. The majority of eligible patients (7/10) underwent Stem Cell Transplantation. Median Progression Free Survival (PFS) and Overall Survival (OS) were 5.2 months and 12.5 months respectively. Conclusion: Our current study shows that Bv used in combination with chemotherapy provides a high CRR and thereby allows SCT in R/R PTCL. The use of Bv treatments in this setting warrants further investigation.